Sign Out
Midazolam (Dormicum) must not be used in patients with known hypersensitivity to benzodiazepines or any of their formulation excipients.
Film-coated tablet: Midazolam (Dormicum) must not be used in patients with: Severe respiratory insufficiency; severe hepatic impairment (benzodiazepines are not indicated to treat patients with severe hepatic impairment as they may cause encephalopathy); sleep apnea syndrome; myasthenia gravis.
Midazolam (Dormicum) tablets should not be given to children, 12 years of age and under, because the available strengths of tablets do not allow for appropriate dosing in this patient population.
Midazolam (Dormicum) tablets should not be given to patients receiving concomitant therapy with very strong CYP3A inducers or inhibitors (ketoconazole, itraconazole, voriconazole, HIV protease inhibitors including ritonavir-boosted formulations), and the HCV protease inhibitors boceprevir and telaprevir (see Interactions).
Continue with Google